Medical Device | June 04, 2026
BPL MedTech unveils new ICU ventilator BPL Vent 300
The ventilator features a high-performance turbine capable of delivering up to 240 L/min peak flow
The ventilator features a high-performance turbine capable of delivering up to 240 L/min peak flow
The move signals a major expansion in access to next-generation weight-loss therapies
At the center of the project is a new cosmetics line developed through collaboration between industry and medicine
The filing is backed by Phase III data from the lidERA Breast Cancer study
Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials is the bioequivalent to the reference listed drug (RLD) Halaven injection of Eisai, Inc.
The transaction includes an upfront payment of $1.55 billion, along with up to $1.1 billion in regulatory and commercial milestone payments
First immunotherapy combination approved in the US for BCG-naïve high-risk NMIBC demonstrates a 32% reduction in the risk of disease recurrence, progression, or death
The approval is supported by results from the Phase 3 SWOG 1826 trial
The approval marks a major milestone in the global fight against antimicrobial resistance
The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,
Subscribe To Our Newsletter & Stay Updated
